Bifogade filer
PDF
Kurs & Likviditet
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
ChemoTech expects to sign three new commercial contracts in Q4-2023, in addition to the three already communicated, thereby pushing the previous stated target of 15 commercial contracts in India during Q4-2023 to Q1-2024.
The reason for postponing the goal of 15 commercial installations in India to Q1-2024 is linked to delays in negotiations as a result of the recent cyclone "Michaung" in the Chennai area.
"The discussions and contract signings are taking somewhat longer due to this external event, but is by no means affected in terms of how they are progressing. We have not lost one single account in our discussions so far and foresee to have them completed in the first quarter of next year", says Mohan Frick, CEO of Scandinavian ChemoTech.
ChemoTech continues to make strong progress in discussions with Indian hospitals and the company's commercial and clinical teams have presented at three tumour board meetings with around 30 oncology experts during the last two months. ChemoTech has also started discussions with leading cancer institutes in India which has translated in further evaluations of the TSE-technology with the explicit goal to make it part of the routine treatment protocol.
For further information please contact:
Mohan Frick, CEO
Phone: +46 (0)10-218 93 00
E-mail: ir@chemotech.se
This disclosure contains information that ChemoTech is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 11-12-2023 14:30 CET.
Scandinavian ChemoTech AB (publ)
ChemoTech is a Swedish medical technology company based in Lund that has developed a patented technology platform to offer cancer patients access to a new treatment alternative, Tumour Specific Electroporation™ (TSE), available for treatment of both humans and animals. There are a large number of cancer patients whose tumours for various reasons cannot be treated by conventional methods but where TSE can be a solution. Therefore, the company continuously evaluates new opportunities and areas of application for the technology. ChemoTech's shares (CMOTEC B) are listed on Nasdaq First North Growth Market in Stockholm and Redeye AB is the company's Certified Adviser. Read more at: www.chemotech.se.